Advertisement

 

 

Comparison of the long-term efficacy between entecavir and tenofovir in treatment- naïve chronic hepatitis B patients.

Comparison of the long-term efficacy between entecavir and tenofovir in treatment- naïve chronic hepatitis B patients.
Author Information (click to view)

Park JW, Kwak KM, Kim SE, Jang MK, Suk KT, Kim DJ, Park SH, Lee MS, Kim HS, Park CK,


Park JW, Kwak KM, Kim SE, Jang MK, Suk KT, Kim DJ, Park SH, Lee MS, Kim HS, Park CK, (click to view)

Park JW, Kwak KM, Kim SE, Jang MK, Suk KT, Kim DJ, Park SH, Lee MS, Kim HS, Park CK,

Advertisement

BMC gastroenterology 2017 03 0917(1) 39 doi 10.1186/s12876-017-0596-7

Abstract
BACKGROUND
There have been limited studies directly comparing the long-term efficacy between entecavir (ETV) and tenofovir disoproxil fumarate (TDF). This study was aimed to compare the long-term efficacy between them in treatment-naïve chronic hepatitis B (CHB).

METHODS
Out of 345 CHB patients who received first line therapy with ETV (n = 200) or TDF (n = 145) in a cohort, 210 patients were analyzed using propensity score matching, at a ratio of 1:1.

RESULTS
Two groups showed no difference in baseline characteristics. During the follow-up of 12 months, HBV DNA levels were similarly suppressed in both groups (ETV vs. TDF; -5.01 vs. -5.242 log10IU/mL, P = 0.559). At month 12, both groups showed no difference in terms of the serologic, biochemical and virologic (VR) response. In multivariate analysis, the initial virologic response at 3 months (IVR-3) was independent factor for VR at 1 year. During the long-term follow-up, HBV DNA levels were more strongly suppressed by TDF than ETV in hepatitis B e antigen (HBeAg) positive patients (P = 0.035), especially with high viral load (P = 0.012), although there was no significant difference in overall VR between two groups. The type of antivirals was not an independent factor for long-term VR.

CONCLUSIONS
Although either ETV or TDF, overall, may show a comparable long-term antiviral efficacy in treatment-naïve CHB, TDF might be better regimen than ETV in the subgroup of HBeAg-positive CHB, especially with a higher HBV DNA levels.

Submit a Comment

Your email address will not be published. Required fields are marked *

3 × four =

[ HIDE/SHOW ]